“Right-to-Try” experimental drugs: an overview

  title={“Right-to-Try” experimental drugs: an overview},
  author={Vijay K. Mahant},
  journal={Journal of Translational Medicine},
  • V. Mahant
  • Published 2020
  • Medicine, Computer Science
  • Journal of Translational Medicine
The “Right-to-Try” experimental drugs act passed by Donald Trump in 2018 provides an opportunity of early access to experimental drugs for the treatment of life-threatening diseases and a potential boon to many young and under-capitalized biotechnology or pharmaceutical companies. The pros and cons of experimental drugs, including a number of “cutting edge” scientific, clinical, and a number of synergistic approaches such as artificial intelligence, machine learning, big data, data refineries… Expand
1 Citations

Tables and Topics from this paper

Measuring Attitudes About Genomic Medicine: Validation of the Genomic Orientation Scale (GO Scale).
The GO Scale may be used to characterize attitudinal perspectives among patients, clinicians, and the public and may also be useful in evaluating shifts in attitude over time, for example, following educational interventions, which has not been feasible to date. Expand


Trump signs bill to give patients right to try drugs
  • O. Dyer
  • Medicine
  • British Medical Journal
  • 2018
The US Congress has passed a controversial bill that effectively ends the Food and Drug Administration’s control over access to unapproved drugs sought by patients who believe that they have run outExpand
A new era of unapproved drugs: the case of Abigail Alliance v Von Eschenbach.
A rehearing of the Abigail Alliance for Better Access to Developmental Drugs v Von Eschenbach case may reshape the regulation and sale of pharmaceuticals and, perhaps, encourage increased use of unregulated drugs. Expand
Some Lingering Concerns about the Precision Medicine Initiative
  • M. Rothstein
  • Medicine
  • The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • 2016
The NIH Cohort Program will assemble a repository of genomic information along with health and other records from 1 million volunteers to develop individually tailored, precision medicine approaches to predictive health assessments, prevention, and therapies. Expand
Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access
It is found that patients and their families experience mixed results, but still gravitate towards the use of online campaigns out of desperation, lack of reliable information about treatment access options, and in direct response to limitations of the current fragmented structure of expanded access regulation and policy currently in place. Expand
Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
This review describes recent insights and methods on how to integrate patient perspectives into personalized medicine and provides an overview of the most used patient-reported outcome measures in IPF to facilitate choices for both researchers and clinicians when incorporating the patient voice in their research and care. Expand
Panomics for Precision Medicine.
The ultimate hope of integrative panomics is that it will lead to the discovery and application of novel markers and targeted therapeutics that drive forward a new era of 'precision medicine' where inter-individual variation is accounted for in the treatment of patients. Expand
Gut microbiome modulates efficacy of immune checkpoint inhibitors
It is proposed that Gut microbiome is an important predictive factor, and manipulation of gut microbiome is feasible to elevate response rate in ICIs therapy, and possible antitumor mechanism of specific commensals in ICI treatment. Expand
Informed Consent in Right-To-Try Cases.
  • J. Piel
  • Medicine
  • The journal of the American Academy of Psychiatry and the Law
  • 2016
There has been a surge since 2014 in state legislation addressing the topic of access to investigational treatments for persons who are terminally ill and have exhausted standard medical management.Expand
Adp53 (Gendicine) 12 Years in Clinic – The First Approved Gene Therapy Product for Cancer
Comparing with the first-line standard therapies, intratumor injection of Gendicine combined with chemotherapy and radiotherapy resulted in response rate significantly higher than chemo or radiotherapy alone. Expand
Multi-omics approaches to disease
This review provides an overview of omics technologies and methods for their integration across multiple omics layers and offers the opportunity to understand the flow of information that underlies disease. Expand